For patients with functional high-risk myeloma (e.g., relapse ≤18 mo of 1st-line Tx), any good summary of data for functional high-risk vs high-risk FISH vs both?
Summarizing what I found so far, but I know I must be missing a few studies!
2/ In KarMMa-2 Cohort A from #ASH22 by @szusmani@DrKrinaPatel et al, 37 patients with #MMsm enrolled in early ide-cel trial for functional high-risk.
Of n=22 with evaluable FISH (I wish it were a little higher), 45% didn't have any high-risk features.
4/ In @BloodCancerJnl analysis of @theMMRF CoMMpass data set for "functional super-high-risk" #MMsm patients: relapse ≤12 mo of Tx initiation) *or* ≤MR to induction...
(1/20) Just finished leading a conference about #COVID19 and hematology. >50% of my citations were preprints, so that got me thinking: why write my own preprint when I can just do a tweetorial? So here goes: 🎺🥁[fanfare] COVID-19 for the HEME CONSULT fellow or attending.
(2/20) This is a saga about #COVID19 and non-malignant hematology* in three chapters: 1) COVID-19 and lymphocytes 2) COVID-19 and platelets 3) COVID-19 and RBCs
* Or should I say, “classical hematology.”
(3/20) For #COVID19 and lymphocytes: Lymphopenia is bad, and lymphocyte % (on diff) starting <20% ➡️5% over time is even worse. Mehh methods but good commentary, spelled out in this excellent tweetorial by @Leo_ReapDO